KRAS and non-small cell lung carcinoma: In addition to these findings, recent studies have also made important advances in the development of small-molecule RAS inhibitors as well as their mechanisms for inhibiting the RAS pathway.37–39 However, developing therapeutic approaches for pan-KRAS-mutant NSCLC via MEK-based combined strategies remains a challenge.